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Abstract
In the last decade, metabolism has been recognized as a major determinant of immunological processes. During an inflam-
matory response, macrophages undergo striking changes in their metabolism. This metabolic reprogramming is governed by 
a complex interplay between metabolic enzymes and metabolites of different pathways and represents the basis for proper 
macrophage function. It is now evident that these changes go far beyond the well-known Warburg effect and the perturbation 
of metabolic targets is being investigated as a means to treat infections and auto-immune diseases. In the present review, we 
will aim to provide an overview of the metabolic responses during proinflammatory macrophage activation and show how 
these changes modulate the immune response.
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Introduction
As a part of the innate immune system, peripheral mono-
cytes are amongst the first responders of an infection, indis-
criminately engulfing everything that does not originate 
from the host organism. Macrophages belong to the group 
of mononuclear phagocytes and are present in almost every 
corner of the body. Depending on their exact location in 
the organism, different types of macrophages, with func-
tions specifically tailored to the tissue they inhabit, have 
been identified throughout the last century. These types 
include, e.g., peripheral macrophages in the blood, perito-
neal macrophages, pulmonary macrophages, Kupffer cells 
in the liver, and microglia in the brain [1]. The tissue resi-
dent variants can either originate from the proliferation of 
embryonic progenitor-derived macrophages, or the recruit-
ment and subsequent proliferation of mononuclear cells 
from the blood. Independent of their origin or localization 
in the body, the aim during an infection remains the same: to 
engulf pathogens and present their antigens to members of 
the adaptive immune system, thereby initiating the immune 
response. During this process, macrophages also produce 
and secrete a wide array of cytokines, which further activate 
fellow immune cells. Depending on the type of threat recog-
nized by the macrophage, these cytokines can be of a pro- or 
anti-inflammatory nature. The transition of macrophages to 
an inflammation-promoting phenotype is induced by proin-
flammatory cytokines as well as pathogen-associated molec-
ular patterns (PAMPs), such as lipopolysaccharide (LPS), 
which are primarily sensed by members of the Toll-like 
receptor (TLR) family [2]. Macrophages activated in such 
a way are often termed classically activated macrophages 
(CAMs) or M1 macrophages [3]. These cells exhibit a strong 
bactericidal and phagocytotic potential, and aim to fend off 
infections in the body. On the other hand, quiescent mac-
rophages can be directed towards an anti-inflammatory phe-
notype by the action of anti-inflammatory cytokines, para-
sitic infections, and damage-associated molecular patterns 
(DAMPs). The resulting cells play an important role in tissue 
repair and wound healing and are referred to as alternatively 
activated macrophages (AAMs), or M2 macrophages [3]. 
M1 macrophages represent a first line of defense, rapidly 
acting against an arising infection, whereas M2 macrophages 
exhibit long-term functions in resolving the inflammatory 
response [4]. Classification into the M1 and M2 phenotype 
is, however, subject to recent discussion and should be used 
with caution [5]. In the context of in vitro experiments, M1 
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usually describes macrophages stimulated with LPS and 
interferon gamma (or M[LPS + IFNγ]), whereas M2 equates 
to IL-4 stimulation (or M[IL-4]). Macrophages activated 
by other factors are mostly classified as M1- or M2-like. 
Although such a broad classification can be performed based 
on the response of distinct pro- and anti-inflammatory mark-
ers, the overall phenotype of these cells often differs sub-
stantially from the M[LPS + IFNγ] and M[IL-4] states [6]. 
It should also be noted that the environment of macrophages 
in vivo is presumably too complex to allow for such specific 
polarization phenotypes, and rather gives rise to several 
intermediate activation states [7]. Nevertheless, analysis 
of the M[LPS + IFNγ] or M[LPS] and M[IL-4] cells has 
proven to be a very useful tool in elucidating the molecular 
mechanisms that orchestrate the inflammatory response.
Both, classically and alternatively activated macrophages, 
are not only characterized by the production and upregula-
tion of a distinct set of cytokines and genes, but also by a 
profound and specific rearrangement of metabolic fluxes. 
In general, M1 macrophages switch from oxidative phos-
phorylation (OxPhos) to glycolysis for ATP generation. In 
turn, M2 cells go the opposite direction with moderate gly-
colytic and high OxPhos activity [8]. An increasing number 
of studies currently add more and more metabolic features 
to the portfolio of each activation state, demonstrating how 
metabolic changes are not just the result of the inflamma-
tory response, but rather a critical modulator of the entire 
process. In the following, we will describe which metabolic 
events take place in the different parts of cellular energy 
metabolism when macrophages encounter proinflammatory 
stimuli, and discuss how these processes interfere with the 
immune response.
Glycolysis
Classically activated macrophages rely on glycolysis 
for energy generation
First evidence of metabolic reprogramming in activated 
macrophages was provided by a study published in 1970 
[9]. Gordon C. Hard compared several biochemical param-
eters of peritoneal macrophages from normal mice and 
mice infected with Corynebacterium ovis. He showed that 
while activated macrophages produced more lactate, oxy-
gen uptake was higher in unstimulated cells. This indicated 
that activated macrophages mainly rely on aerobic glyco-
lysis (commonly referred to as the Warburg effect [10]) for 
ATP generation. His findings were confirmed in another 
study 16 years later, which provided further information 
on changes in the activity of individual glycolytic enzymes 
as well as enzymes involved in fatty acid and amino acid 
metabolism [11]. At the time, however, it could not be 
determined which factors regulate these metabolic changes 
and whether altered metabolism plays a role in modulating 
the inflammatory response. Recent studies have picked up 
on these questions and made use of modern methods and 
technologies to shed light on the role of metabolism during 
inflammation. In the last decade, many enzymes involved in 
glycolysis have been found to also act as major players in 
controlling inflammation. In this section, we will focus on 
the individual components of glycolysis and discuss how 
they are involved in the inflammatory process. A schematic 
overview of these components is also depicted in Fig. 1.
GLUT1
The uptake of glucose into the cell is generally mediated by 
carriers of the SLC2 family [12]. In both resting and M(LPS) 
macrophages, this task is predominantly carried out by the 
GLUT1 uniporter [13, 14]. Overexpression of GLUT1 in 
LPS-primed, murine macrophages has been shown to boost 
glycolytic activity as well as the production of the proin-
flammatory cytokines IL-6 and TNFα, demonstrating a 
causal link between glucose metabolism and the immune 
response [14]. GLUT1 overexpressing cells further exhibited 
decreased OxPhos activity and accumulated intermediates of 
the pentose phosphate pathway (PPP)—both of these obser-
vations have previously been demonstrated to be character-
istic features of M1 polarized macrophages [6]. In contrast, 
competitive inhibition of glycolysis via 2-deoxyglucose 
(2-DG) dampened the production of the proinflammatory 
cytokine IL-1β [15]. Interestingly, the connection between 
glycolytic flux and IL-1β involves action of the transcrip-
tion factor hypoxia inducible factor-1α (HIF-1α), which is 
stabilized by accumulation of succinate and the production 
of mitochondrial ROS (mROS) upon TLR4 stimulation (also 
see section “Succinic acid”).
Hexokinase
Once glucose has passed the cytosolic membrane, it is phos-
phorylated to glucose-6-phosphate to initiate glycolysis—a 
reaction catalyzed by the hexokinase (HK) enzyme. Besides 
its enzymatic function, HK was recently found to be a sensor 
for the bacterial cell wall degradation product N-acetylglu-
cosamine (NAG) [16]. Bacterial peptidoglycans are usually 
sensed via the cytosolic NOD2 receptor which subsequently 
triggers an inflammatory response. However, this was not the 
case for NAG, which is able to induce NLRP3 inflammas-
ome activation even when NOD2 is not present [17]. Instead, 
NAG binds to HK in a competitive manner, leading to its 
inactivation and dissociation from the mitochondrial outer 
membrane (Fig. 1a) [16]. This dissociation alone is sufficient 
to trigger inflammasome activation, as was shown by the 
application of a peptide competing with HK for binding to 
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the voltage-dependent anion channel (VDAC) located on the 
surface of mitochondria. Interestingly, in this study, 2-DG-
mediated inhibition of HK resulted in increased IL-1β pro-
duction which is in contrast to previous studies demonstrat-
ing a dampened IL-1β response when the same inhibitor was 
applied [15, 18]. This ambiguity can possibly be explained 
by differences in stimulation conditions, 2-DG concentra-
tion, cell viability, or the timing of hexokinase inhibition 
[19]. Nonetheless, this example clearly demonstrates that 
further research is required to identify the determinants that 
eventually lead to seemingly opposite results when applying 
the same treatment.
6‑Phosphofructo‑2‑kinase/
fructose‑2,6‑biphosphatase
The next enzyme in the glycolytic chain associated with 
inflammatory regulation is the 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase enzyme (PFK2; encoded by the 
PFKFB3 gene) which catalyzes the conversion of fructose 
6-phosphate (F6P) to fructose-2,6-bisphosphate (F-2,6-P2). 
The latter acts as an allosteric activator of PFK1 and as a 
repressor of fructose-1,6-bisphosphatase (FBPase), respec-
tively [20]. As a result, increased concentrations of F-2,6-P2 
potentiate glycolytic flux (Fig. 1c). Upon classical activa-
tion or stimulation with TLR-2, -3, -4, or -9 agonists, mac-
rophages were shown to exhibit a switch from the liver form 
of PFK2 (L-PFK2) to its ubiquitous form (uPFK2) [21]. 
While the enzymatic activity of L-PFK2 is relatively low, 
the more active uPFK2 maintains higher F-2,6-P2 levels, 
resulting in increased glycolytic activity. Induction of the 
uPFK2 isoform has been described under hypoxic condi-
tions, where it is triggered by stabilization of HIF-1α [22]. 
A similar behavior was observed in response to classical 
activation [21], where HIF-1α is stabilized by accumulat-
ing succinate [15] and increased mitochondrial ROS [23]. 
Fig. 1  Schematic depiction of 
metabolic changes associated 
with glucose metabolism in 
proinflammatory macrophages
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Intriguingly, the switch to the uPFK2 isoform still occurred 
in HIF-1α−/− macrophages, suggesting that uPFK2 expres-
sion is regulated through a mechanism independent of 
HIF-1α. Expression of several inflammatory transcripts 
(IL-6, IP-10, NOS2, and Arg-1) in macrophages activated 
with LPS and IFN-γ was also unaffected by the ablation of 
HIF-1α. A RNAi-mediated knockdown of uPFK2, on the 
other hand, resulted in decreased expression of the proin-
flammatory markers NOS2 and COX-2. These results point 
towards a role for PFK2 in the metabolic activation of pro-
inflammatory macrophages. A recent study confirmed this 
notion by demonstrating the importance of PFK during 
viral infections [24]. In this model, PFK-induced glycolytic 
metabolism supported the phagocytosis and elimination of 
viruses by macrophages.
Glyceraldehyde 3‑phosphate dehydrogenase
A remarkable, yet unexpected function was recently 
unveiled for the glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) enzyme. Besides its well-known catalytic function 
in glycolysis, it was shown that GAPDH can repress transla-
tion of the proinflammatory cytokine TNFα by binding to 
its mRNA (Fig. 1d) [25]. Although GAPDH was known to 
act as a RNA-binding protein (especially of AU-rich ele-
ments) [26], its role during the proinflammatory response 
was previously unheard of. Millet and colleagues demon-
strated an inverse relationship between glycolytic activity 
and GAPDH-mediated repression of TNFα expression, sug-
gesting that GAPDH is only able to carry out one of its two 
tasks at a time [25]. Indeed, the previous studies have shown 
that the binding of GAPDH to generic AU-rich elements 
is inhibited by its substrate glyceraldehyde 3-phosphate 
[27] and its cofactor  NAD+ [26]. Mechanistically, GAPDH 
was found to inhibit TNFα translation by binding to the 
3′ untranslated region of TNF mRNA. This binding could 
be reversed by either knocking down GAPDH or increasing 
glycolytic flux via treatment with insulin or other chemical 
effectors. The observed effects on TNFα production under 
these conditions were, however, relatively small as compared 
to mechanisms regulating the transcription of TNF mRNA 
[28]. Accordingly, the described mechanism seems to be a 
way of fine-tuning the inflammatory response, rather than 
a critical determinant of TNF expression. It should also be 
noted that the regulatory activity of GAPDH might be espe-
cially relevant during the first 4 h after the proinflammatory 
stimulus, since another study found no connection between 
glycolytic activity and TNFα production at later timepoints 
[15]. The same mechanism was recently also described for 
the regulation of IFN-γ by GAPDH in T cells [29] and it will 
be interesting to see if a similar kind of regulation will hold 
true for other metabolic enzymes in the future.
Pyruvate kinase
The last, rate-limiting step of glycolysis is represented by the 
conversion of phosphoenolpyruvate to pyruvate—a reaction 
catalyzed by the pyruvate kinase (PK) enzyme. In almost all 
cell types (with the exception of liver and red blood cells), 
this enzyme exists in two different isoforms, termed PKM1 
and PKM2, both of which are encoded by the same gene via 
alternative splicing [30, 31]. While PKM1 is mostly pre-
sent as a homotetramer with high enzymatic activity, the 
PKM2 isoform predominantly exists as a monomer or dimer. 
Although mono- or dimeric PKM2 exerts a lower enzymatic 
activity, it has been shown to be an important factor driv-
ing glycolysis and lactate production in cancer cells [32]. 
This effect is explained by the transition of dimeric PKM2 
from the cytosol to the nucleus, where it acts as a transcrip-
tion factor to promote the expression of glycolytic enzymes 
by interacting with HIF-1α [33]. Interestingly, this switch 
from PKM1 to PKM2, as well as translocation of PKM2 
to the nucleus was also observed upon TLR4 activation 
of murine macrophages [34]. In response to LPS, nuclear, 
dimeric PKM2 was shown to form a complex with HIF-1α 
that enhances transcription of IL-1β by binding to its pro-
motor (Fig. 1e). When the emerging PKM2 was, however, 
forced into the enzymatically active tetrameric state via 
treatment with small-molecule activators, the proinflam-
matory response to LPS was dampened. The inhibitory 
effect of PKM2 activation on the production of IL-1β was 
also confirmed in macrophages infected with M. tubercu-
losis in vitro. In this setup, small-molecule-induced PKM2 
tetramerization, additionally, boosted levels of IL-10, indi-
cating a role of PKM2 in macrophage polarization. On the 
metabolic level, chemical tetramerization of PKM2 impaired 
glycolysis and succinate accumulation—two metabolic 
events commonly upregulated during proinflammatory mac-
rophage activation (also see section “Succinic acid”). This 
effect on both glycolysis and succinate accumulation appears 
to be dependent on HIF-1α, since isoform-specific deletion 
of PKM2 decreased levels of HIF-1α and the expression of 
its downstream targets IL-1β and lactate dehydrogenase A 
(LDHA). Another LPS-induced event that could be allevi-
ated by activation of PKM2 was the accumulation of the 
PPP-intermediate ribose 5-phosphate, suggesting a role for 
PKM2 in regulating carbon flux between glycolysis and the 
PPP.
Pentose phosphate pathway
Production of ROS and RNS
An upregulation of the pentose phosphate pathway (PPP) in 
activated murine macrophages was already described in the 
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late 1970s [35]. Another study confirmed this finding and 
demonstrated that the expression of glucose-6-phosphate 
dehydrogenase (G6PDH), the first and rate-limiting enzyme 
of the PPP, is enhanced in response to LPS (Fig. 1b) [36]. 
Although these early studies already suggested an involve-
ment of the PPP in the inflammatory response, the molecular 
mechanisms underlying this metabolic adaptation remained 
elusive. The two main tasks of the PPP are (1) to provide 
precursors for nucleotide and amino acid synthesis and (2) 
to generate NADPH, which is required for the synthesis of 
fatty acids as well as for the regeneration of glutathione 
(GSH) [37]. While the regeneration of GSH serves as a 
means to alleviate oxidative stress, activated macrophages 
also use PPP-derived NADPH to generate reactive oxygen 
species (ROS). The high oxidation potential of these ROS 
is exploited to kill pathogens in the phagosome [38, 39], 
but ROS can also influence various cellular processes by 
oxidizing redox-sensitive residues of proteins [40, 41]. The 
controlled, enzymatic generation of ROS is mainly mediated 
by seven different isoforms of the NADPH oxidase (NOX) 
[42, 43]. Knockout of NOX1 and NOX2 has recently been 
shown to impair the monocyte-to-macrophage differentia-
tion as well as M2 polarization, demonstrating the impor-
tance of controlled ROS production for macrophage function 
[44]. In addition to ROS, reactive nitrogen species (RNS) 
such as nitric oxide (NO) have been found to amplify the 
proinflammatory phenotype [45]. In macrophages, NO can 
be produced by the inducible nitric oxide synthase (iNOS 
or NOS2), which generates NO as a byproduct during the 
conversion of arginine to citrulline [46]. Upregulation of 
this reaction has already been found to occur in LPS and 
IFNγ stimulated macrophages in the 1980s [47, 48], and was 
subsequently established as a clear marker of M1 polariza-
tion [49]. Mechanistically, NO induces a nitrosylation of 
iron–sulfur proteins, leading to their inactivation [50]. In the 
proinflammatory macrophage, this mechanism decreases the 
activity of two members of the mitochondrial electron trans-
port chain: complex I [51] and cytochrome c oxidase [52]. 
Accordingly, NO is one of the factors which push activated 
macrophages towards a metabolic phenotype characterized 
by low mitochondrial OxPhos and high glycolytic activity. A 
recent study performed in a murine model found that a wide 
range of enzymes can be modified via the S-nitrosylation of 
cysteine residues [53]. These enzymes are found in almost 
all parts of central carbon metabolism including glycolysis, 
gluconeogenesis, tricarboxylic acid cycle, and oxidative 
phosphorylation, highlighting the importance of NO as a 
regulator of metabolism. Interestingly, both isocitrate dehy-
drogenase (IDH) and succinate dehydrogenase (SDH, com-
plex II of the ETC) were also among the identified proteins 
[53]. A decrease in activity of both of these enzymes has 
recently been discovered to play a major role for the course 
and severity of an inflammatory response in macrophages 
(also see sections “Succinate accumulation” and “Metabolic 
reprogramming assists in itaconic acid production”) [15, 54].
In contrast to M1 polarized cells, M2 macrophages 
mostly convert arginine to ornithine instead, which is used 
to synthesize polyamines that aid in tissue-repair functions. 
This differential metabolism of arginine was reported to be 
dependent on the activity of different isoforms of HIF [55]. 
While the HIF-1α isoform promotes the synthesis of NO 
and M1 polarization, the HIF-2α isoform induces arginase 
activity and M2 polarization. The dependence of both NOX 
and iNOS on the cofactor NADPH makes the PPP a key 
regulator for the production of ROS and RNS and, thus, the 
inflammatory response.
The PPP can be separated into two distinct phases. In a 
first series of reactions, glucose-6-phosphate (G6P) is con-
verted to ribulose 5-phosphate (oxidative phase). During this 
phase, 2 mol of NADPH are produced per mol of G6P in the 
reactions catalyzed by the G6PD and 6-phosphogluconate 
dehydrogenase (PGD) enzymes. The second, non-oxidative 
branch of the PPP consists of a series of carbon-backbone 
rearrangements which supply precursors for amino acid and 
nucleotide synthesis or feed carbon atoms back into glyco-
lysis. Interestingly, the expression levels of G6PD and PGD 
were found to be elevated [36, 54, 56], and the relative car-
bon flux through the oxidative part of the PPP was increased 
in activated macrophages [54]. Overexpression of G6PD 
stimulated, whereas its siRNA-mediated knockdown attenu-
ated, the expression of several proinflammatory cytokines, 
including IL-6, IL-1β, MCP-1, and TNFα [56]. The levels of 
both NOX2 and iNOS as well as ROS production were also 
correlated to the abundance of G6PD protein. This finding 
supports the hypothesis that cytokine expression is regulated 
by ROS/RNS, which is further confirmed by the fact that the 
observed effects could be partially reversed by the action of 
radical scavengers.
Role of CARKL
Haschemi et al. have shown that expression of the carbohy-
drate kinase-like protein (CARKL) rapidly decreases upon 
TLR4 activation of both human and murine macrophages 
[57]. CARKL was found to act as a non-protein kinase, cat-
alyzing the formation of sedoheptulose-7-phosphate from 
sedoheptulose—an orphan reaction of the PPP (Fig. 1b). 
Loss of this enzyme was shown to be one of the factors 
that contribute to both cytokine production and metabolic 
reprogramming in LPS-activated macrophages. Overexpres-
sion of CARKL limited flux though the PPP and induced a 
striking shift towards a more oxidized redox state, manifest-
ing itself in increased NAD/NADH and GSSG/GSH ratios. 
These shifts seem to be the result of limited NADPH avail-
ability, which is vital for the reduction of redox couples. 
Production of superoxide radicals (O2∙−), a typical feature 
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of proinflammatory macrophages, was also blunted upon 
CARKL overexpression. Again, NADPH limitation could 
explain this behavior, given the fact that classically acti-
vated macrophages (CAMs) exploit the NADPH oxidase 
system for ROS production [39, 44, 58, 59]. In activated 
macrophages, this might imply that the increased produc-
tion of NADPH via the PPP is not only necessary to produce 
ROS, but also to ensure a sufficient supply of antioxidants 
to prevent the adverse effects which the ROS might cause. 
Overexpression of CARKL further led to a reduction in gly-
colytic flux, which is usually strongly upregulated in proin-
flammatory macrophages [15, 21, 34]. The production of key 
proinflammatory transcripts (i.e., TNFα, IL,-1β, IL-6, and 
IL-13R) also appeared to be dependent on the absence of 
CARKL. Concurrently, overexpression of CARKL pushed 
the expression of anti-inflammatory markers, as for example 
IL-10 and the IL-4 receptor. Stimulation with agents that 
drive M2-like polarization, i.e., IL-4 and IL-13, induced a 
mild boost in CARKL levels, thus even suggesting a regula-
tory role for CARKL in macrophage polarization. Notably, 
the CARKL-mediated effects on macrophage metabolism 
and cytokine production are directly linked to its enzymatic 
activity, as the effects were not observed in CARKL vari-
ants carrying a mutation in the catalytic site of the protein. 
This study nicely shows how the inflammatory response can 
be regulated and controlled by modulating metabolic flux.
Succinic acid
Succinate accumulation
One of the most profound changes in the metabolism of 
M1-like polarized macrophages is the intracellular accu-
mulation of high amounts of the TCA cycle intermediate 
succinate [15]. This observation was first made in a study 
investigating the influence of glycolytic activity on cytokine 
production. Interestingly, inhibition of glycolysis using 
2-DG decreased the levels of both IL-1β production and 
succinate accumulation, suggesting a functional connection 
between the two. The previous studies on cancer metabo-
lism have shown that succinate can induce stabilization of 
the transcription factor HIF-1α [60]. Under normoxic con-
ditions, HIF-1α is hydroxylated by cytosolic HIF-α prolyl 
hydroxylase (PHD) enzymes and subsequently degraded. 
During this reaction, α-ketoglutarate is converted to succi-
nate. Accumulating succinate is transported from the mito-
chondria to the cytosol via the dicarboxylate carrier (DIC). 
In the cytosol, it induced product inhibition of PHDs, and 
thus, prevents hydroxylation and degradation of HIF-1α 
(Fig. 2). In the activated macrophage, HIF-1α then pro-
ceeds to push aerobic glycolysis and lactate production, as 
well as the transcription of IL-1β by binding to its promotor 
[34]. The intracellular level of succinate is mainly regulated 
by the activity of SDH. Treatment with the SDH-inhibitor 
butylmalonate or cell-permeable diethylsuccinate increased 
intracellular succinate levels and HIF-1α and IL-1β protein 
abundance in LPS-activated macrophages [15]. The depend-
ence of IL-1β expression on HIF-1α was further demon-
strated by the application of HIF-1α−/− macrophages, which 
showed a dampened response to diethylsuccinate treatment.
SDH‑mediated ROS production
Although many of the effects discussed above can be 
explained by accumulating succinate, a more recent study 
highlighted the importance of SDH activity as a main driver 
of proinflammatory macrophage activation [23]. The authors 
applied dimethylmalonate (DMM) which is hydrolyzed in 
the cell to form malonate—a competitive inhibitor of SDH-
mediated succinate oxidation [61]. Intriguingly, treatment 
with DMM increased succinate levels, but failed to stabilize 
HIF-1α and increase IL-1β expression. This seems especially 
odd, given that these expected outcomes were observed in a 
previous study using the SDH-inhibitor butylmalonate [15]. 
In contrast, DMM decreased LPS-induced IL-1β mRNA, 
pro-IL-1β, and HIF-1α protein (but not TNF-α) and boosted 
IL-10. These data indicate that, in addition to the cytosolic 
effects of succinate on PHDs, its oxidation in the mitochon-
dria is of vital importance for proinflammatory macrophage 
activation. This notion is supported by a recent report, 
showing that the recognition of bacteria induces changes in 
the architecture of the ETC [62]. When macrophages were 
incubated with living bacteria, the abundance of complex 
I-associated structures decreased, while complex II activity 
was stimulated. Interestingly, treatment with heat-inactivated 
bacteria did not evoke this response to the same extent, 
strongly suggesting that pathogen viability plays a vital role 
regarding the intensity of the induced immune response. It 
was further shown that LPS-stimulated macrophages mainly 
rely on glycolysis for ATP generation and, as a consequence, 
exhibit a higher mitochondrial membrane potential (ΔΨm) 
[23]. This increase in ΔΨm emerges due to an accumulation 
of protons in the mitochondrial intermembrane space when 
the ATP synthase is inactive. When analyzing the impact of 
the increase in ΔΨm on macrophage activation, the authors 
found that its function lies in the production of mitochon-
drial ROS (mROS), which act as a signal to drive IL-1β pro-
duction. mROS are most likely produced via reverse electron 
flow from complex II to complex I of the ETC, following 
succinate oxidation (Fig. 2) [63, 64]. Treatment with several 
ROS scavengers abolished LPS-induced mROS and signifi-
cantly decreased IL-1β expression [23]. The same effect was 
observed in macrophages overexpressing alternative oxi-
dase (AOX)—an enzyme which oxidizes excess electrons 
in the ubiquinone pool without affecting ΔΨm. Strikingly, 
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overexpression of AOX also increased the survival of mice 
injected with LPS [23]. The influence of increased mROS 
on IL-1β is likely mediated via the stabilization of HIF-1α, 
as was previously demonstrated [65]. These results are in 
line with a second study which showed a similar effect of 
complex I inhibition by metformin on both ROS generation 
and IL-1β production [66]. The fact that mROS and HIF-1α 
regulate the production of IL-1β, but not TNF-α, indicate a 
specificity of mitochondria regarding cytokine production. 
Of note, it was previously found that TLR signaling induces 
not only the production of mROS, but also the recruitment of 
mitochondria to phagosomes, indicating a bactericidal role 
of mROS [67]. Furthermore, mROS was shown to modify 
cytokine production by preventing the dephosphorylation of 
mitogen-activated protein kinases (MAPKs) [68] and acti-
vating the NLRP3 inflammasome [69, 70], which is involved 
in the maturation of IL-1β. The various roles of mROS (and 
ROS in general) highlight the importance of the cellular 
redox state, which is directly coupled to the metabolic activ-
ity of a cell, for the course of the inflammatory process.
Role of the aspartate‑arginosuccinate shunt
Besides succinate, the TCA cycle intermediate malate was 
also found to accumulate at later stages of the inflammatory 
response (24 h after LPS stimulation) [54]. Intriguingly, a 
[U-13C]glutamine tracer-based approach revealed a con-
siderably higher amount of 13C-atoms in succinate as com-
pared to malate. These observations can only be explained 
by increased activity of a glutamine-independent pathway 
which also contributes to the malate pool [71]. Based on 
similarities of pool size ratios between unstimulated and M1 
Fig. 2  Schematic depiction of 
metabolic changes associated 
with mitochondrial metabolism 
in proinflammatory mac-
rophages
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macrophages as well as the corresponding 13C-labeling pat-
terns, the authors identified the aspartate-arginosuccinate 
shunt (AASS) as a source of malate [54]. The AASS con-
nects the TCA cycle with the urea cycle and feeds the malate 
pool indirectly by producing fumarate. At the same time, 
nitric oxide can be produced from argininosuccinate via 
the NO cycle (Fig. 2). The significance of this pathway was 
highlighted by chemical inhibition of the AASS in M1 mac-
rophages, which led to decreased NO and IL-6 production 
and iNOS expression as well as a normalization of glycolytic 
activity and mitochondrial respiratory function. The latter is 
most likely due to the decrease in NO, which has been shown 
to suppress mitochondrial respiration in dendritic cells [72].
Pseudohypoxic metabolism of proinflammatory 
macrophages
The LPS-induced stabilization of HIF-1α by cytosolic succi-
nate [15] and mROS [23], even under normoxic conditions, 
pushes cells into a state termed pseudohypoxia [60]. These 
findings led to the speculation that LPS-induced HIF-1α 
stabilization uncouples carbon flux from glycolytic pyru-
vate into the TCA cycle by inhibiting pyruvate dehydroge-
nase (PDH) activity. This posttranscriptional inhibition is 
carried out by the HIF-1α target pyruvate dehydrogenase 
kinase (PDK) which inactivates PDH by phosphorylation. 
A study by Meiser et al. set out to test this hypothesis and 
demonstrated that M(LPS) macrophages sustained PDH 
activity, although HIF-1α protein was stabilized [73]. Sur-
prisingly, the expression of Pdk1 in murine macrophages 
even decreased in response to LPS, eventually leading to a 
slight increase in pyruvate oxidation by PDH (Fig. 2). Inhi-
bition of pyruvate entry into the TCA cycle via chemical 
inhibition of the mitochondrial pyruvate carrier 1 (MPC1) 
resulted in decreased expression levels of iNOS, Irg1, and 
Tnfα, as well as lower intracellular levels of itaconic acid. 
The expression of IL-1β was only slightly lowered follow-
ing MPC1 inhibition. These results highlight the fact that 
M(LPS) macrophages rely on mitochondrial pyruvate oxida-
tion for the production of key cytokines and the synthesis of 
itaconic acid. The latter plays an important role during later 
stages of the immune response where it regulates proinflam-
matory cytokine production through inhibition of SDH [74, 
75]. Activation of aerobic glycolysis through the action of 
HIF-1α and PDK was also found to play an essential role in 
macrophage mobilization and migration [76]. When PDK 
was inhibited by treatment with dichloroacetic acid (DCA), 
Semba et al. observed a decrease in cell migration, eventu-
ally leading to systemic inflammation in vivo [76].
Another metabolic feature commonly observed as a 
result of HIF-1α stabilization is the IDH-mediated, reduc-
tive carboxylation of α-ketoglutarate to isocitrate [77–79]. 
Under hypoxic conditions, where pyruvate entry into the 
TCA cycle is restricted, this reaction serves to produce 
citrate from glutamine to compensate for the decreased 
contribution from glucose. The generated citrate is then 
cleaved to produce cytosolic acetyl-CoA, which can be 
used for lipid synthesis. Interestingly, this metabolic phe-
notype was also not observed in M(LPS) macrophages, 
although glutamine uptake was increased as compared to 
resting macrophages [73]. It was shown that M(LPS) mac-
rophages mainly rely on glucose-derived carbon for fatty 
acid synthesis, with the relative contribution from glucose 
to fatty acid carbons being around five times as high as 
the respective contribution from glutamine. These results 
point towards the existence of one or more yet unknown 
factors, which regulate the activities of PDK and reductive 
glutamine metabolism in LPS-activated macrophages. The 
importance of fatty acid synthesis is further highlighted by 
a study investigating the role of the mitochondrial citrate 
carrier—the first step in channeling citrate towards fatty 
acid synthesis [80]. The citrate carrier was found to be 
upregulated upon LPS stimulation and silencing or inhibi-
tion of the carrier reduced the production of nitric oxide, 
ROS, and prostaglandin E2.
Protein succinylation
Succinate can further interfere with cellular metabolism 
via the succinylation of protein lysine residues (Fig. 2). 
Proteins that have been shown to undergo succinylation 
include important metabolic enzymes, including aspartate 
aminotransferase, glutamate dehydrogenase, malate dehy-
drogenase, and citrate synthase [81]. The degree of protein 
lysine succinylation is mainly regulated by the action of the 
 NAD+-dependent desuccinylase and demalonylase SIRT5 
[82, 83]. The expression of this enzyme was decreased in 
LPS-stimulated macrophages, while protein succinylation 
was doubled [15]. Both SIRT5 expression and global protein 
succinylation could be inhibited by treatment with 2-DG in 
a dose-dependent manner. Furthermore, LPS treatment led 
to a decrease in the NAD/NADH ratio, which might reflect 
limited availability of  NAD+ for SIRT5-mediated protein 
succinylation. The shift towards  NAD+ also provides fur-
ther proof of the overall metabolic phenotype of CAMs with 
high glycolytic and low OxPhos activity. One recently dis-
covered target of SIRT5 is PKM2 [84]. It was shown that 
SIRT5 activates PKM2 via desuccinylation in LPS-primed 
macrophages to boost the expression of IL-1β (also see 
section “Pyruvate kinase”). Further pathways affected by 
SIRT5-mediated protein desuccinylation include fatty acid 
β-oxidation and the synthesis of ketone bodies [85]. These 
findings clearly suggest a regulatory role for protein succi-
nylation during the innate immune response which needs to 
be further investigated.
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Succinate as a signaling metabolite
Apart from its intracellular functions, succinate can also act 
as an autocrine and paracrine signaling metabolite [86]. Suc-
cinate can either be released into the extracellular milieu by 
damaged or necrotic cells [87], or when intracellular suc-
cinate accumulates—as for example during inhibition of 
SDH [88]. Two scenarios potentially observed during pro-
inflammatory macrophage activation in vivo. Extracellular 
succinate is recognized by the G protein-coupled receptor 
GPR91 (also referred to as SUCNR1), which was found to 
be expressed on the cell surface of mature dendritic cells and 
macrophages (Fig. 2) [89, 90]. Its activation, in combina-
tion with TLR3 or TLR7 activation, augmented expression 
of the proinflammatory cytokines IL-1β and, interestingly, 
also TNF-α [90]. A recent study demonstrated a GPR91/
succinate-dependent feed-forward loop of macrophage acti-
vation, ultimately leading to increased production of IL-1β 
[86]. Disturbance of this mechanism, e.g., by administration 
of GPR91 antagonists, was proposed as a novel approach to 
treat patients with rheumatoid arthritis.
Itaconic acid
Inhibition of bacterial growth
Another very exciting metabolite in the context of proin-
flammatory macrophage activation is itaconic acid (or meth-
ylenesuccinic acid). This metabolite was mainly believed 
to be a microbial metabolite until 2011, when Strelko and 
colleagues reported on the production of itaconic acid in 
activated macrophage cell lines and primary macrophages 
[91]. Two years later, immune-responsive Gene 1 (Irg1) was 
identified as the gene encoding the cis-aconitate decarbox-
ylase (CAD) that catalyzes itaconic acid production from 
the TCA cycle intermediate cis-aconitate (Fig. 2) [92]. Irg1 
protein expression is massively potentiated in macrophages 
subjected to LPS or Th1 cytokines and is regulated by the 
interferon regulatory factor 1 (IRF1) [93]. At the time, the 
primary function of itaconic acid was suspected to be the 
inhibition of bacterial growth for microorganisms feeding 
on acetate or fatty acids [94]. This effect is mediated by 
itaconic acid inhibiting the isocitrate lyase (ICL) enzyme 
of the glyoxylate shunt [95]—a pathway absent in mam-
malian cells. In Mycobacterium tuberculosis, the ICL 
enzyme was further described to exhibit methylisocitrate 
lyase (MCL) activity. Methylisocitrate is an intermediate of 
the 2-methylcitrate cycle [96]—a pathway required for the 
detoxification of propionyl-CoA produced by the degrada-
tion of cholesterol from host macrophages [97]. This side-
activity of ICL was also inhibited by the action of itaconic 
acid, confirming ICL as one of its targets [92]. To achieve 
itaconic acid concentrations that are sufficient to effectively 
inhibit bacterial growth, macrophages accumulate high 
amounts of the metabolite, most likely in the cytosol and/
or phagolysosomes. It was previously shown that the Irg1 
protein associates with mitochondria [98]; however, it is still 
not clear where exactly itaconic acid is produced. One pos-
sibility is that itaconic is produced inside the mitochondria 
and then transported to the cytosol or the phagolysosomes 
via one of the numerous mitochondrial carriers. A recent 
study supports this notion by showing that CAD-containing 
mitochondria closely associate with Legionella-containing 
vacuoles in murine BMDMs [99]. This might hint towards 
a directed trafficking of itaconic acid to the location where 
it is required for the inhibition of bacterial growth. Alterna-
tively, CAD might be localized at the outer mitochondrial 
membrane with its catalytic activity directly in the cytosol.
Inhibition of SDH
Although the anti-microbial activity of itaconic acid has 
been well established, more recent studies have demon-
strated that the role of itaconic acid in the context of inflam-
mation seems to go far beyond inhibiting bacterial growth. 
It was shown that, in addition to inhibiting bacterial ICL, 
itaconic acid also acts as a competitive inhibitor of succinate 
dehydrogenase (SDH or complex II of the mitochondrial 
electron transport chain) in LPS-activated macrophages 
(Fig. 2) [74, 75]. Theoretically, itaconic acid could also 
directly contribute to the intracellular succinate pool by 
interconversion of the two metabolites, as was previously 
described for Pseudomonas sp. [100] and isolated liver mito-
chondria [101]. This possibility was elegantly excluded by 
applying a 13C stable isotope labeling approach, showing 
that, in murine macrophages, carbon atoms from itaconic 
acid do not end up in succinate [74]. Macrophages isolated 
from Irg1−/− mice accumulated succinate to a lower extent as 
compared to their wild-type counterparts when challenged 
with LPS. Accordingly, inhibition of SDH by itaconic acid 
seems to be partially responsible for the accumulation of 
succinate observed in CAMs and thus plays a crucial role in 
governing the inflammatory response by regulating HIF-1α 
stabilization [15, 23]. Indeed, the administration of dimethyl 
itaconate, a potentially membrane permeable non-ionic form 
of itaconic acid, drastically suppressed the expression of the 
proinflammatory markers iNOS, IL-6, IL-18, IL-1β, and IL-
12p70 [75]. The levels of TNFα remained unchanged, which 
is in accordance with the previous work on the influence 
of SDH and succinate on cytokine production [15, 23]. In 
contrast, ablation of Irg1 had an amplifying effect on the 
production of the cytokines and inflammatory markers 
mentioned above (but not TNFα). Mechanistically, itaconic 
acid-mediated SDH inhibition might lead to the observed 
decrease in SDH-derived mitochondrial ROS (mROS), 
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which have been reported to affect inflammasome priming 
[102]. The authors of that study could further show that the 
abundance of HIF-1α protein is increased in the absence of 
itaconic acid and decreased when exogenous itaconate is 
added. These observations indicate that the stabilization of 
HIF-1α and the subsequent promotion of IL-1β expression 
might rather be mediated by the inhibition of SDH activity 
than signaling through accumulating succinate. Either way, 
the influence of Irg1 and itaconic acid on cytokine produc-
tion clearly places them on the map as vital anti-inflamma-
tory players, regulating the innate immune response.
Metabolic reprogramming assists in itaconic acid 
production
In addition to the metabolic rewiring caused by the action 
of itaconic acid itself, another metabolic switch potentially 
supports itaconic acid production. Using a combined sys-
tem approach of metabolomics and transcriptomics data, Jha 
et al. identified transcriptional downregulation of isocitrate 
dehydrogenase 1 (IDH1) and the subsequent disruption of 
TCA cycle flux as a major feature of M1 polarization (Fig. 2) 
[54]. This breakpoint at the site of IDH led to an accumula-
tion of citrate and isocitrate, which represent the indirect pre-
cursors of itaconic acid. Based on 13C labeling data, no car-
bon atoms from glucose were passed on to α-ketoglutarate 
in M1 macrophages. Instead, glucose-derived carbon flux 
was redirected towards itaconic acid production, suggesting 
that glucose is an important carbon source for itaconic acid. 
However, only one out of the five carbon atoms of itaconic 
acid is derived from glycolytic acetyl-CoA. The remaining 
four carbons are derived from oxaloacetate, which can be 
produced from glutamine via glutaminolysis, or from glu-
cose via the pyruvate carboxylase reaction. In zebrafish, it 
was recently shown that fatty acid oxidation for the produc-
tion of mitochondrial ROS is dependent on the presence 
of CAD protein [103]. However, a role for fatty acids as 
a carbon source for itaconic acid production seems rather 
unlikely, given the highly glycolytic nature of M1 polarized 
macrophages. Meiser et al. analyzed which carbon sources 
contribute to itaconic acid production in RAW 264.7 cells 
and found that 27 and 59% of itaconic acid carbon atoms 
are derived from glucose and glutamine, respectively [73]. 
However, the carbon sources for itaconic acid production are 
likely dependent on the activity of other metabolic enzymes 
such as IDH and SDH and might, thus, change during the 
course of an infection.
The decrease in oxidative TCA cycle metabolism result-
ing from IDH1 downregulation [54] presumably contributes 
to the decrease in respirational activity, commonly observed 
in M1 macrophages [6]. Given the fact that these experi-
ments were only performed after 20–24 h of stimulation 
and that the reduced activity of IDH1 is due to a decrease 
in its transcription, IDH1 might still be active during the 
early stages of infection. It would be interesting to get a 
more detailed picture of the dynamics of IDH1 inactiva-
tion during the course of an inflammatory response, since 
itaconic acid peaks around 10 h after stimulation [92]. Such 
experiments could help to shed light on the influence of 
IDH1 on itaconic acid production. Another open question 
concerns the IDH isoforms involved in this process. In their 
study, Jha et al. only indicate a role for the cytosolic isoform 
IDH1, although an involvement of the mitochondrial IDH2 
seems more intuitive based on the observed implications for 
TCA cycle activity. Regardless of the isoform involved, the 
simultaneous decrease of both IDH and SDH activity during 
M1 polarization seems to play a vital role in controlling the 
inflammatory response in murine macrophages. Nonethe-
less, future investigations will have to show how these find-
ings translate to other cell types and species.
Are itaconic acid and dimethyl itaconate suited 
for investigating the intracellular mode of action 
of itaconic acid?
One recently published article adds a bitter taste to the 
results obtained from experiments where itaconic acid or 
dimethyl itaconate used to study the mechanistic effects of 
itaconic acid on cellular metabolism. ElAzzouny and col-
leagues synthesized 13C-labeled variants of both substances 
and demonstrated that itaconic acid is not taken up, and 
dimethyl itaconate is not metabolized by bone marrow-
derived macrophages [104]. Remarkably, exogenous itaconic 
acid nonetheless managed to boost intracellular succinate 
levels. This would suggest that the effects observed in this 
and previous studies [74, 75] are not mediated through direct 
inhibition of SDH by itaconic acid, but rather through its 
binding to cell surface receptors. One potential candidate 
is the succinate receptor GPR91, given the structural simi-
larity between succinate and itaconate [86]. The observed 
inconsistencies regarding the uptake of itaconic acid and the 
metabolization of dimethyl itaconate could potentially also 
be explained by differences in the experimental setup of the 
various studies (e.g., incubation times). However, if it holds 
true that itaconic acid and dimethyl itaconate are not suitable 
agents to increase intracellular itaconate levels, the previous 
studies will have to be re-interpreted accordingly.
Inhibition of substrate‑level phosphorylation
Another mode of action which was recently described for 
itaconic acid is the abolition of mitochondrial substrate-
level phosphorylation (SLP, Fig. 2) [105]. During SLP, 
ATP or GTP is generated by a direct transfer of phosphate 
groups from phosphorylated intermediates to ADP or GDP, 
respectively. In mitochondria, SLP is mainly occurs during 
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the succinate-CoA ligase reaction. This reaction becomes 
especially important under conditions where ATP genera-
tion via oxidative phosphorylation is impaired. Treatment of 
isolated liver mitochondria with itaconic acid dose-depend-
ently inhibited and even reversed the directionality of the 
adenine nucleotide translocator, suggesting SLP inhibition. 
How the inhibitory effect of itaconic acid on SLP affects the 
metabolism and polarization state of macrophages, however, 
remains unclear. Given the inhibitory effect of itaconic acid 
on SDH, a component of the mitochondrial ETC, SLP inhi-
bition seems counterintuitive, since it would make it harder 
for the already challenged macrophage to ensure sufficient 
energy generation. There could, however, be a benefit dur-
ing infection when looking at the effect of SLP inhibition 
in the infective organism: succinate-CoA ligase-mediated 
SLP is essential for the survival of procyclic Trypanosoma 
brucei and potentially other microorganisms [106]. Besides 
the well-established inhibition of ICL, inhibition of SLP 
could be a second target for itaconic acid to impede micro-
bial growth.
Glutathione
Given the high rate of ROS production during classical acti-
vation, macrophages need a means to control and prevent 
excessive radical formation, which would otherwise lead to 
chronic inflammation. The main antioxidant used for this 
purpose is the tripeptide GSH (γ-l-glutamyl-l-cysteinyl-
glycine). GSH can reach intracellular concentrations of 
up to 10 mM and plays an important role in maintaining 
cellular redox homeostasis [107, 108]. On the molecular 
level, ROS oxidize redox-sensitive cysteine residues in pro-
teins to sulfenic, sulfinic, and sulfonic acid groups, thereby 
modifying protein tertiary structure and activity [109]. 
For sulfenic and sulfinic acid residues, this process can be 
reversed by GSH in combination with a respective reduc-
tase enzyme. Furthermore, GSH can be covalently bound 
to protein cysteine residues when ROS are present, as was 
recently shown for peroxiredoxin-2 [110] and the transcrip-
tion factor HIF-1α [111]. In the case of HIF-1α, glutath-
ionylation led to its stabilization. The deglutathionylation 
process is catalyzed by the glutaredoxin-1 enzyme, whose 
deletion increased HIF-1α activity and positively influenced 
ischemic revascularization. Modulation of HIF-1α activity 
via glutathionylation might also have significant implica-
tions for macrophage activation, as HIF-1α is involved in 
orchestrating the metabolic response of proinflammatory 
macrophages [15, 23, 34]. One especially interesting enzyme 
regarding glutathionylation in the context on inflammation 
is glutathione transferase omega 1 (GSTO1). Knockdown 
of this enzyme in macrophages was followed by a decrease 
in NOX1 expression and ROS production upon LPS 
stimulation [112]. GSTO1-deficient macrophages did not 
switch to the highly glycolytic phenotype usually observed 
in M(LPS) macrophages, possibly due to decreased levels 
of HIF-1α protein [113]. Accumulation of the immunome-
tabolite succinate was also blocked in GSTO1-deficient 
cells. These results suggest a role for GSTO1 in the LPS-
TLR4 proinflammatory pathway and make GSTO1 and GSH 
metabolism attractive targets for potential pharmacological 
interventions to treat chronic inflammation.
Another strategy in which macrophages use GSH to 
protect themselves from oxidative damage was recently 
unveiled. Lok et al. reported on a storage and transport sys-
tem for NO, which helps macrophages in delivering NO 
to tumor cells without suffering from its cytotoxic effects 
themselves [114]. To this end, NO is sequestered as a 
dinitrosyl-dithiol iron complex (DNIC) by the glutathione 
S-transferase P1 (GSTP1) enzyme. In contrast to NO, DNICs 
do not induce cell death via the release of iron via the MRP1 
transporter. In activated macrophages, both GSTP1 and 
MRP1 were upregulated and MRP1 was shown to medi-
ate the export of DNICs. Decreased expression of GSTP1 
and MRP1 was associated with NO-mediated cytotoxicity, 
strongly suggesting that this storage and transport system 
plays a vital role for macrophages in protecting themselves 
from the effects of their own RNS.
The importance of GSH for immunological processes is 
further underlined by a recent study which indentified the 
catalytic subunit of glutamate cysteine ligase (GCLc), the 
rate-limiting enzyme in GSH synthesis, as a critical compo-
nent during T cell activation [115]. While GCLc-deficient 
T cells still exhibited normal, early activation, they were 
not able to reprogram their metabolism and proliferate upon 
activation. Ablation of the Gclc gene successfully prevented 
auto-immunity but also impaired antiviral defense in vivo.
Branched‑chain aminotransferase 1
Branched-chain aminotransferases (BCATs) are enzymes 
that convert the branched-chain amino acids valine, leucine, 
and isoleucine into the respective branched-chain ketoac-
ids (BCKAs). BCAT1 was previously found to be highly 
expressed in tumors carrying non-mutated IDH1/2 alleles, 
where it promoted tumor cell proliferation and invasiveness 
[116, 117]. The function of BCATs in inflammation was, 
however, unknown. A recent study reported that human 
primary macrophages predominantly express cytosolic 
BCAT1 and that chemical inhibition of this isoform results 
in decreased oxygen consumption and glycolysis [118]. 
BCAT1 inhibition also downregulated the expression of 
Irg1 and, in turn, itaconic acid production in M(LPS) mac-
rophages. The mRNA and protein levels of both IL-1β and 
HIF-1α were not affected by these metabolic changes during 
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early activation (3 h after LPS treatment), but IL-1β pro-
tein levels were significantly decreased later on (24 h after 
LPS treatment). These findings highlight the importance of 
choosing the correct timepoint when performing research on 
the biochemistry of macrophage activation. As an example, 
Irg1 expression peaks at 6 h after LPS stimulation, whereas 
itaconic acid levels reach their maximum after 8–10 h [74, 
92]. Depending on the underlying biological question, the 
timing of the experiment will have a crucial effect on the 
obtained result.
It will be interesting to see, if and how BCAT1 affects 
metabolic features of activated macrophages, especially the 
accumulation of succinate, SDH activity, and the production 
of mROS. Administration of the selective BCAT1 inhibitor 
ERG240 (a leucine analogue) to mice resulted in reduced 
severity of immune-mediated inflammation in vivo, indicat-
ing that BCAT1 inhibition could also be of potential thera-
peutic interest [118]. A second study on the role of BCAT1 
in macrophages found that glioblastoma cells secrete 
BCKAs via the monocarboxylate carrier 1 (MCT1) and 
that these BCKAs are taken up by tumor-associated mac-
rophages [119]. BCKA uptake is potentially mediated by the 
MCT1 and/or MCT4 carriers, both of which are expressed 
in macrophages. Subsequently, the BCKAs are aminated via 
BCAT1 to form either valine, leucine, or isoleucine (Fig. 2). 
Although a 13C tracing approach revealed no contribution of 
BCKAs to TCA cycle intermediates, macrophages treated 
with BCKAs exhibited impaired phagocytic capacity. Thus, 
these results identify BCKAs as a means of cancer cells to 
suppress immune function and sustain tumor growth.
Prevention of chronic inflammation 
by the action of IL‑10
An interesting study recently investigated the role of IL-10 
in alleviating an ongoing inflammatory response [120]. 
IL-10 is an anti-inflammatory cytokine, which is produced 
by activated immune cells and sensed via the IL-10 recep-
tor (IL-10R) [121]. Although IL-10R is expressed by many 
immune cells, macrophages have been shown to be the pri-
mary target of IL-10 [122, 123]. Mutations in either IL-10 
or its receptor have been associated with chronic inflam-
mation, underlining the importance of IL-10 signaling in 
regulating the immune response. On the metabolic level, 
macrophages from IL-10−/− mice exhibited higher glyco-
lytic rates, but decreased OxPhos activity as compared to 
wild-type macrophages, and both effects could be rescued 
by the addition of exogenous IL-10 [120]. The inhibitory 
effect of IL-10 on glycolysis was shown to be mediated by 
downregulation of glycolytic genes as well as the preven-
tion of GLUT1 translocation from intracellular vesicles to 
the plasma membrane. IL-10−/− cells further accumulated 
ROS-producing mitochondria with a loss of ΔΨm. In 
wild-type cells, such mitochondria are usually subjected 
to mitophagy, as excessive ROS can amplify an inflam-
matory response in various ways (see section “Hexoki-
nase” for more details). The observed effects seem to be 
mediated by IL-10 induced inhibition of mTORC1 via 
STAT3 and DDIT4. mTORC1 acts as a driver of glucose 
and lipid metabolism as well as an inhibitor of autophagy 
[124]. Upon TLR4 activation, mTORC1 is initially active 
to allow for proinflammatory metabolic reprogramming 
with high glycolytic rates and mitochondrial ROS produc-
tion [15, 23, 125]. In IL-10−/− macrophages, mTORC1 
signaling is more persistent, which eventually pushes mac-
rophages towards an uncontrolled, proinflammatory state. 
Interestingly, the IL-10 induced expression of DDIT4 is 
independent of HIF-1α, a known regulator of DDIT4 in 
hypoxia [126].
NOX4 and fatty acid oxidation
NADPH oxidases are one of the main sources for ROS 
in activated macrophages [42, 43] and as such they have 
a significant impact on the course of an inflammatory 
response. Besides its ROS-generating function, the mito-
chondrial NOX4 isoform was also found to control fatty 
acid β-oxidation [127]. Knockout of NOX4 reduced the 
expression of carnitine palmitoyltransferase 1A (CPT1A). 
This enzyme catalyzes the transfer of a fatty acid acyl-group 
from coenzyme A to carnitine—a crucial step for the initia-
tion of fatty acid oxidation. The concomitant decrease in 
fatty acid oxidation resulted in decreased NLRP3 inflam-
masome activation and reduced production of the proinflam-
matory cytokines IL-1β and IL-18 [127]. A similar effect 
was observed when treating BMDMs with the CPT1 inhibi-
tor etomoxir. Ablation of NOX4 in a mouse model led to 
improved survival during NLRP3-mediated Streptococcus 
pneumoniae infection. These results suggest that fatty acid 
oxidation acts as a driver of proinflammatory activation by 
promoting NLRP3 inflammasome activation. This finding 
came as a surprise, given that CPT1A was previously found 
to be necessary for the polarization of alternatively activated 
M[IL-4] macrophages [128]. Accordingly, fatty acid oxida-
tion seems to take different roles, depending on the cellular 
context. One additional factor which should be taken into 
account is that results obtained from studies using etomoxir 
should be interpreted with caution. A recent study showed 
that etomoxir exerted the same effect on M2 polarization 
in both wild-type and CPT2-deficient BMDMs [129]. This 
clearly demonstrates that the effects of this inhibitor on M2 
polarization are caused by yet unknown mechanisms which 
are independent of CPT inhibition.
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Summary
The increasing number of studies on immunometabo-
lism clearly reflects the importance of metabolism as a 
critical modulator of inflammation. Recent studies have 
shown that metabolism reprogramming is a key prereq-
uisite for proper macrophage function, rather than merely 
a side effect of macrophage activation. Since metabolism 
is highly dynamic, it provides the perfect basis to allow 
for a swift response to environmental changes, which is 
especially important for the adaptation to pathogen infec-
tion. This adaptation is governed by the interplay of many 
metabolic enzymes, some of which exhibit previously 
unknown functions to drive inflammation. For example, 
GAPDH was shown to bind to and repress the transla-
tion of TNFα mRNA [25]. Both the complex interactions 
between numerous metabolic enzymes, pathways, and 
metabolites as well as changes in their behavior over the 
course of the activation process make this topic very chal-
lenging to investigate [130].
Notably, a large number of the metabolic features 
found in proinflammatory macrophages are also observed 
in cancer cells. This does not come as a surprise, given 
the fact that both cell types face demanding conditions 
with the need for high amounts of energy to support either 
immune functions or rapid growth. Thus, the most strik-
ing similarities are found in the way which their energy 
metabolism is rearranged: both cell types mainly rely on 
aerobic glycolysis for energy generation and exhibit low 
rates of mitochondrial OxPhos. In some cases, activated 
macrophages and cancer cells even exploit the same regu-
latory mechanisms to reach their goals, as was shown, e.g, 
for the switch to PKM2 [34], stabilization of HIF-1α [15, 
131], or expression of BCAT1 [118].
One of the most remarkable metabolic changes in acti-
vated macrophages is the CAD-mediated production of 
itaconic acid. This metabolite stands out, as its production 
in mammals seems to be confined to cells of macrophage-
lineage [132]. Even though an increasing number of stud-
ies on the role and importance of Irg1 and itaconic acid are 
currently being published, some open questions remain. 
One exciting topic is the intracellular compartmentaliza-
tion and trafficking of itaconic acid: Is itaconic acid pro-
duced by the mitochondria or in the cytosol, and which 
carriers mediate its transport between these two compart-
ments and phagolysosomes? Newly developed methods 
could help to address these questions [133]. Another 
question to be answered is: Is itaconic acid degraded, or 
simply secreted from the cell, as some studies suggest [75, 
91]? If the latter is the case, could it potentially be used 
as a biomarker for infectious diseases? What happens to 
itaconic acid once the proinflammatory response is over? 
And lastly: Are there still unknown functions of itaconic 
acid that are waiting to be unveiled? A recent study found 
that several cell lines, including a murine macrophage 
line, produce itaconyl-CoA from itaconic acid [134]. 
Accumulating itaconyl-CoA was identified as a cofactor-
inactivating inhibitor of the mitochondrial  B12-dependent 
methylmalonyl-CoA mutase (MUT). This enzyme plays 
a vital role in the catabolism of odd chain fatty acids and 
branched-chain amino acids. If and how itaconyl-CoA-
mediated MUT inhibition affects macrophage activation 
will need to be investigated in future studies.
In addition to the ways in which metabolism controls 
macrophage activation that are discussed in this review, 
metabolic activity and the accumulation of metabolic 
intermediates are also tightly coupled to epigenetic modi-
fications [135, 136]. Metabolic products such as acetyl-
CoA, α-ketoglutarate, fumarate,  NAD+, or S-adenosylme-
thionine affect epigenetic modifications either by acting 
as substrates or indirectly by modulating the activity of 
epigenetic enzymes. These processes have recently been 
shown to have a strong impact on immunological pro-
cesses such as trained immunity [137] and are an exciting 
field for further investigations.
The aim of all immunological research is to increase 
our understanding of the mechanisms involved the immune 
response to find new ways to treat or prevent diseases. In 
the case of macrophage activation, there are two directions 
which can potentially lead to novel therapeutic approaches: 
inducing a shift from M1 to M2 would be beneficial for the 
treatment of chronic and auto-immune diseases, whereas 
enhancement of the M1 phenotype could help cope with 
infectious diseases. Metabolic intervention is a promis-
ing tool to achieve these goals, given the importance of 
metabolic reprogramming for macrophage activation. One 
major problem, however, is that metabolic targets are, in 
most cases, not specific to macrophages or immune cells, 
which can leads to off-target effects in other tissues. Fur-
thermore, immune cells might respond differently to a 
given treatment, depending on the tissue environment they 
are facing. Future research will have to set out to overcome 
these problems to discover novel therapeutic approaches.
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